Yaqi Zhao, MSc, St. Jude Children’s Research Hospital, Memphis, TN, briefly discusses how novel targeted antibodies could transform the treatment landscape for patients with B-cell acute lymphoblastic leukemia (B-ALL). Currently, the standard of care for patients with B-ALL consists of multiagent chemotherapy. However, chemotherapy provides few treatment options for patients with relapsed or refractory (R/R) disease. Several recently approved novel targeted antibody therapies, including blinatumomab and inotuzumab are promising treatment options for these patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.